 Patients receive ascorbic acid intravenously IV over 90-120 minutes three times per week at least 24 hours apart and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. 